Dianthus Sold $98.1 Million Of Stock In One Quarter, More Than The First Half Combined

The biotech holds $1.2 billion and says that funds operations into 2030, yet it opened a new $500 million stock-sale program.

Share
Dianthus Sold $98.1 Million Of Stock In One Quarter, More Than The First Half Combined

Dianthus Therapeutics, a clinical-stage biotech developing treatments for severe autoimmune diseases, raised $98.1 million by selling stock through at-the-market programs in the third quarter, according to its 10-Q filed Wednesday. That is more than the $58.7 million it raised the same way in the first half, even though the company reports about $1.2 billion in cash and investments.

ATM sales speed up

An at-the-market program lets a company sell shares into the open market over time. Nine-month sales netted $156.8 million. No such sales happened in the first nine months of 2025.

The prior quarterly filing had reported $58.7 million from 1,123,126 shares for the first six months of 2026.

The $200 million initial program is now fully used, with 3,632,534 shares sold for $200.0 million in gross proceeds. On September 18, 2026, the company signed a new agreement to sell up to $500 million more. The filing says no sales have been made under it so far.

Shares outstanding reached 56,295,226 at September 30, up from 54,798,338 at June 30. The market value was $4.6 billion after Wednesday's session.

A balance sheet built on stock

Dianthus has funded itself almost entirely by selling equity: $1.0 billion from public offerings, $423.5 million from private placements and $200.0 million from ATM programs. A March 2026 public offering at $81.00 a share brought in about $719.0 million before fees.

The company says cash and investments of $1.2 billion should last into 2030, the same runway it cited last quarter. It also warns it will need more capital and that equity raises dilute existing holders.

The net loss for the nine months was $137.7 million, against $97.9 million a year earlier, and the accumulated deficit stands at $474.4 million. Research and development spending was $128.8 million, up from $85.7 million. Stock-based compensation was $35.2 million, against $16.8 million, according to the cash flow statement.

The only revenue is license revenue from Tenacia, which licenses rights in Greater China: $1.2 million for the quarter and $2.4 million for nine months.

Trial readouts ahead

Dianthus has no approved products. Its lead drug, claseprubart, is an injectable antibody in trials for generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy.

Top-line results from the mid-stage MoMeNtum trial in multifocal motor neuropathy are expected in December 2026, with 46 patients. A late-stage trial in that disease is planned for 2027. The company said it now expects the late-stage CIDP trial to need fewer than 200 participants in its first part, with Part A results by the end of 2027 and Part B by the end of 2028.

The next 10-Q will show whether any of the $500 million program was used, and MoMeNtum results are due in December.

Sources

More on Dianthus Therapeutics

All Dianthus Therapeutics (DNTH) coverage →